December 17, 2012 - Titan Pharmaceuticals Licenses Exclusive Probuphine® Commercialization Rights in U.S. and Canada to Braeburn Pharmaceuticals

November 12, 2012 - Titan Pharmaceuticals Announces Third Quarter 2012 Financial Results

November 7, 2012 - Titan Pharmaceuticals Schedules Conference Call to Review Third Quarter 2012 Financial Results

October 29, 2012 - Titan Pharmaceuticals Announces Submission of New Drug Application for Probuphine for the Treatment of Opioid Dependence

September 14, 2012 - Titan Pharmaceuticals Announces $4.25 Million Stock Purchase and Option Agreement

August 10, 2012 - Titan Pharmaceuticals Announces Second Quarter 2012 Financial Results

August 8, 2012 - Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2012 Financial Results

July 9, 2012 - Titan Completes Preclinical Study of a Continuous, Dopamine Agonist Treatment For Parkinson’s Disease

May 11, 2012 - Titan Pharmaceuticals Announces First Quarter 2012 Financial Results

May 9, 2012 - Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2012 Financial Results

April 20, 2012 - Titan Pharmaceuticals Announces Phase 3 Probuphine®Data Presentation At The American Society Of Addiction Medicine (ASAM) 43Rd Medical-Scientific Conference

April 10, 2012 - Titan Pharmaceuticals to Raise $5.5 Million in Registered Direct Offering

March 16, 2012 - Titan Pharmaceuticals Announces Fourth Quarter and Year-End 2011 Financial Results

March 14, 2012 - Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2011 Financial Results

February 9, 2012 - Titan Pharmaceuticals Announces Positive Results of Six-Month Open-Label Safety Retreatment Study Of Probuphine

February 7, 2012 - Titan Pharmaceuticals to Present at 14th Annual BIO CEO & Investor Conference